SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    A report showing the incidence and mortality of the twenty most common cancers diagnosed in the UK, with analysis by age and sex. Cancer Research UK Mortality Statistics , 2012
  • 2
    Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 114859
  • 3
    Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 150212
  • 4
    de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 114754
  • 5
    Parker CHD, O'Sullivan JM, Fossa SD et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol 2012; 30 (Suppl. 5 abstr 8)
  • 6
    de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 19952005
  • 7
    Scher HFL, Saad F, Taplin M-E et al. S, for the AFFIRM Investigators. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer post docetaxel: results from the phase III AFFIRM study. J Clin Oncol 2012; 30 (Suppl. 5 abstr LBA1)
  • 8
    Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 41122
  • 9
    Langley RE, Godsland IF, Kynaston H et al. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int 2008; 102: 4425
  • 10
    Huggins CH, Hodges CV. Studies on prostate cancer. I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. Cancer Res 1941; 1: 2937
  • 11
    Huggins C, Scott WW, Hodges CV. Studies on prostatic cancer III. The effects of fever, of desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J Urol 1941; 46: 997
  • 12
    Nesbit RM, Plumb RT. Prostatic carcinoma; a follow-up on 795 patients treated prior to the endocrine era and a comparison of survival rates between these and patients treated by endocrine therapy. Surgery 1946; 20: 26372
  • 13
    Nesbit RM, Plumb RT. Treatment of prostatic carcinoma by castration and by administration of estrogenic hormone; a second report on comparison. Univ Hosp Bull 1946; 12: 14
  • 14
    Blackard CE, Doe RP, Mellinger GT, Byar DP. Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 1970; 26: 24956
  • 15
    Byar DP. Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 112630
  • 16
    Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988; 46: 16570
  • 17
    Bailar JC, 3rd, Byar DP. Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer 1970; 26: 25761
  • 18
    Robinson MR. EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Prog Clin Biol Res 1988; 260: 10110
  • 19
    The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 12816
  • 20
    Waymont B, Lynch TH, Dunn JA et al. Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol 1992; 69: 61420
  • 21
    Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998; 52: 25760
  • 22
    Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F, Oliver RT. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU Int 2000; 85: 106973
  • 23
    Burns-Cox N, Basketter V, Higgins B, Holmes S. Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer. Int J Urol 2002; 9: 4314
  • 24
    Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Urol Int 2005; 75: 21721
  • 25
    Shamash J, Powles T, Sarker SJ et al. A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer 2011; 104: 6208
  • 26
    Dearnaley D. Is Stilbestrol the treatment of choice in refractory metastatic prostate cancer? 1997. Clinical benefit and PSA response. Abstract presented at British Prostate Group Spring Meeting
  • 27
    Suciu S, Sylvester RJ, Yamanaka H. Time-dependent prognostic factors in advanced prostatic cancer. Prog Clin Biol Res 1990; 357: 20315
  • 28
    Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 34617
  • 29
    Jazieh A, Munshi NC, Muirhead M, Ross SW. Clinical efficacy of diethylstilbestrol treatment in post orchiectomy progressive prostate cancer. Proc Am Assoc Cancer Res 1994; 35: 233. abstract
  • 30
    Ferro MA, Gillatt D, Symes MO, Smith PJ. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. Urology 1989; 34: 1348
  • 31
    Citrin DL, Kies MS, Wallemark CB et al. A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer. Cancer 1985; 56: 45760
  • 32
    Takezawa Y, Nakata S, Kobayashi M, Kosaku N, Fukabori Y, Yamanaka H. Moderate dose diethylstilbestrol diphosphate therapy in hormone refractory prostate cancer. Scand J Urol Nephrol 2001; 35: 2837
  • 33
    Droz JP, De Smedt E, Kattan J et al. Phase I trial of high-dose fosfestrol in hormone-refractory adenocarcinoma of the prostate. Prostate 1994; 24: 626
  • 34
    Kattan J, Droz JP, Culine S. [High dose fosfestrol in phase I-II trial for the treatment of hormone-resistant prostatic adenocarcinoma]. Bull Cancer 1993; 80: 24854
  • 35
    Williams AR, Whelan P. Use of intravenous fosfestrol tetrasodium (Honvan) infusion in treatment of symptomatic advanced prostate cancer. Prostate Cancer Prostatic Dis 1998; 1: 2047
  • 36
    Shearer RJ, Hendry WF, Ferguson JD. Oestrogen treatment in carcinoma of the prostate. Br Med J 1973; 3: 51
  • 37
    Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer 2009; 7: E716
  • 38
    Qiu CH, Ohe M, Koibuchi N, Matsuzaki S. Apoptosis in the epididymal epithelium of adult male golden hamster exposed to diethylstilbestrol. J Histochem Cytochem 2004; 52: 18792
  • 39
    Robertson CN, Roberson KM, Padilla GM et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996; 88: 90817
  • 40
    Schulz P, Link TA, Chaudhuri L, Fittler F. Role of the mitochondrial bc1-complex in the cytotoxic action of diethylstilbestrol-diphosphate toward prostatic carcinoma cells. Cancer Res 1990; 50: 500812
  • 41
    Hartley-Asp B, Deinum J, Wallin M. Diethylstilbestrol induces metaphase arrest and inhibits microtubule assembly. Mutat Res 1985; 143: 2315
  • 42
    Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004; 91: 491503
  • 43
    deVoogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762. J Urol 1986; 135: 3037
  • 44
    Chang A, Yeap B, Davis T et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14: 22507
  • 45
    Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995; 28: 27383
  • 46
    Bishop MC. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. Br J Urol 1996; 78: 9217; discussion 7–8
  • 47
    Klotz L, McNeill I, Fleshner N. A phase 1–2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999; 161: 16972
  • 48
    Oh WK, Kantoff PW, Weinberg V et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004; 22: 370512
  • 49
    Rosenbaum E, Wygoda M, Gips M, Hubert A, Tochner Z, Gabizon A. Diethylstilbestrol is an active agent in prostatic cancer patients after failure to complete androgen blockade. Proc Am Soc Clin Oncol 2000; 19: abstr 1372
  • 50
    Shamash J, Stebbing J, Sweeney C et al. A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer 2010; 116: 3595602
  • 51
    Danila DC, Morris MJ, de Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496501